Free Trial
→ Elon Musk’s One Stock Retirement Plan (From Brownstone Research) (Ad)tc pixel
NASDAQ:PSNL

Personalis Q3 2026 Earnings Results & Report

Personalis logo
$15.79 +0.04 (+0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$15.80 +0.01 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Personalis missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.32 versus the -$0.2633 consensus estimate, while revenue of $25.60 million topped the $21.54 million estimate by $4.06 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Personalis EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.2633
Beat/Miss
Missed by -$0.0567
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Personalis Revenue Results

Actual Revenue
$25.60 million
Expected Revenue
$21.54 million
Beat/Miss
Beat by +$4.06 million
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Personalis' Q3 2026 Press ReleasePress Release
(8-K)
Personalis' Q3 2026 Quarterly reportQuarterly report
(10-Q)

Personalis Q3 2026 Earnings FAQ

Personalis (NASDAQ:PSNL) reported earnings of -$0.32 per share for Q3 2026, missing the consensus estimate of -$0.2633. The report was announced on Wednesday, November 4, 2026.

Personalis reported revenue of $25.60 million for Q3 2026, against a consensus estimate of $21.54 million.

Personalis Earnings Headlines

PSNL Investigation Reminder: Personalis $16.25 per Share Merger Triggers Investigation on Behalf of Shareholders – Contact BFA Law if You Hold Shares
November 4 at 6:18 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395107/0/en/psnl-investigation-reminder-personalis-16-25-per-share-merger-triggers-investigation-on-behalf-of-shareholders-contact-bfa-law-if-you-hold-shares.html
PSNL Shareholder Notice: Personalis $16.25 per Share Merger Under Investigation on Behalf of Shareholders
November 3 at 6:03 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/psnl-shareholder-notice-personalis-16-25-per-share-merger-under-investigation-on-behalf-of-shareholders-302926940.html
Dollar Reset – Are You Prepared?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
November 4 at 1:00 AM  |  Porter & Company (Ad)
PSNL Legal Notice: Personalis Shareholders are Notified to Contact BFA Law About the Ongoing Investigation into the $16.25 per Share Merger
November 2 at 5:38 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261102384562/en/psnl-legal-notice-personalis-shareholders-are-notified-to-contact-bfa-law-about-the-ongoing-investigation-into-the-16.25-per-share-merger/
Personalis (PSNL) Expected to Release Earnings on Tuesday
November 2 at 2:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173223
PSNL Investigation Reminder: Personalis' $16.25 per Share Merger Is Under Investigation – Contact BFA Law if You Hold Shares
October 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/30/3392115/0/en/psnl-investigation-reminder-personalis-16-25-per-share-merger-is-under-investigation-contact-bfa-law-if-you-hold-shares.html
See More Personalis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Personalis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Personalis and other key companies, straight to your email.

About Personalis

Personalis (NASDAQ:PSNL) is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal. These offerings are intended for applications including cancer profiling, immunotherapy research, treatment selection, and the detection of molecular residual disease.

Founded in 2011 and headquartered in Fremont, California, Personalis serves biopharmaceutical companies, healthcare providers, researchers, and other organizations involved in oncology and genomic medicine. The company became publicly traded on the Nasdaq under the symbol PSNL in 2019.

View Personalis Profile
Earnings Tools